 Hours after psychedelic leader Compass Pathways NASDAQ:CMPS announced Phase IIb results from the largest modern study on a psychedelic substance, the stocks of most psychedelic companies holistically took a nosedive despite generally positive results. Peter Theil-backed Compass published data revealing that a strong dose of its Comp360 medication a psiloCybin NEO:CYBN-derivative in a crystalline form helped reduce depression in patients suffering from the treatment-resistant mental health issue. 